Graig Suvannavejh
Stock Analyst at Mizuho
(4.64)
# 244
Out of 5,182 analysts
178
Total ratings
56.72%
Success rate
26.13%
Average return
Main Sectors:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $20 → $41 | $40.95 | +0.12% | 13 | Apr 2, 2026 | |
| IMMX Immix Biopharma | Maintains: Outperform | $14 → $15 | $9.53 | +57.40% | 2 | Mar 30, 2026 | |
| INSM Insmed | Maintains: Outperform | $204 → $206 | $135.98 | +51.49% | 14 | Mar 25, 2026 | |
| PVLA Palvella Therapeutics | Maintains: Outperform | $205 → $250 | $128.64 | +94.34% | 2 | Feb 25, 2026 | |
| LONA LeonaBio | Upgrades: Outperform | $10 | $8.35 | +19.76% | 1 | Feb 19, 2026 | |
| ERAS Erasca | Maintains: Outperform | $4 → $5 | $19.15 | -73.89% | 1 | Dec 9, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $33 → $54 | $52.95 | +1.98% | 9 | Dec 9, 2025 | |
| BLTE Belite Bio | Upgrades: Outperform | $105 → $194 | $163.06 | +18.97% | 2 | Dec 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $39 → $46 | $31.05 | +48.15% | 21 | Dec 1, 2025 | |
| TARS Tarsus Pharmaceuticals | Initiates: Outperform | $100 | $60.93 | +64.12% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $11.35 | +102.64% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $54 → $56 | $64.49 | -13.16% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $46 | $29.48 | +56.04% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $202 | $187.40 | +7.79% | 22 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2 → $4 | $1.09 | +266.97% | 9 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $0.12 | +25,025.63% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2.5 → $3.5 | $2.35 | +48.94% | 5 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $2.22 | +125.23% | 2 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $5.76 | +73.61% | 2 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $11 | $15.92 | -30.90% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $13.60 | +91.18% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $16.88 | -52.61% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $28.56 | +15.55% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.42 | +435.21% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $10.08 | +634.13% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.30 | -56.56% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $85.20 | -58.92% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $44.11 | -81.86% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $61.60 | -7.47% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $35.38 | -85.87% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $5.49 | +519.31% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $12.81 | +118.58% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $30.64 | +1.17% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $380 | $14.12 | +2,591.22% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.40 | +239.29% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $23.42 | +53.71% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $28.47 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $4.52 | +718.58% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $201.22 | -36.39% | 1 | Sep 14, 2020 |
Apellis Pharmaceuticals
Apr 2, 2026
Maintains: Neutral
Price Target: $20 → $41
Current: $40.95
Upside: +0.12%
Immix Biopharma
Mar 30, 2026
Maintains: Outperform
Price Target: $14 → $15
Current: $9.53
Upside: +57.40%
Insmed
Mar 25, 2026
Maintains: Outperform
Price Target: $204 → $206
Current: $135.98
Upside: +51.49%
Palvella Therapeutics
Feb 25, 2026
Maintains: Outperform
Price Target: $205 → $250
Current: $128.64
Upside: +94.34%
LeonaBio
Feb 19, 2026
Upgrades: Outperform
Price Target: $10
Current: $8.35
Upside: +19.76%
Erasca
Dec 9, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $19.15
Upside: -73.89%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $33 → $54
Current: $52.95
Upside: +1.98%
Belite Bio
Dec 2, 2025
Upgrades: Outperform
Price Target: $105 → $194
Current: $163.06
Upside: +18.97%
Harmony Biosciences Holdings
Dec 1, 2025
Maintains: Outperform
Price Target: $39 → $46
Current: $31.05
Upside: +48.15%
Tarsus Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $100
Current: $60.93
Upside: +64.12%
Nov 19, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $11.35
Upside: +102.64%
Nov 18, 2025
Maintains: Neutral
Price Target: $54 → $56
Current: $64.49
Upside: -13.16%
Nov 11, 2025
Maintains: Outperform
Price Target: $44 → $46
Current: $29.48
Upside: +56.04%
Nov 6, 2025
Maintains: Outperform
Price Target: $200 → $202
Current: $187.40
Upside: +7.79%
Sep 12, 2025
Maintains: Neutral
Price Target: $2 → $4
Current: $1.09
Upside: +266.97%
Sep 8, 2025
Initiates: Outperform
Price Target: $30
Current: $0.12
Upside: +25,025.63%
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.35
Upside: +48.94%
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.22
Upside: +125.23%
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $5.76
Upside: +73.61%
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $15.92
Upside: -30.90%
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $13.60
Upside: +91.18%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $16.88
Upside: -52.61%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $28.56
Upside: +15.55%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.42
Upside: +435.21%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $10.08
Upside: +634.13%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.30
Upside: -56.56%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $85.20
Upside: -58.92%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $44.11
Upside: -81.86%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $61.60
Upside: -7.47%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $35.38
Upside: -85.87%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $5.49
Upside: +519.31%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $12.81
Upside: +118.58%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $30.64
Upside: +1.17%
Mar 2, 2021
Initiates: Sell
Price Target: $380
Current: $14.12
Upside: +2,591.22%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.40
Upside: +239.29%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $23.42
Upside: +53.71%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $28.47
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $4.52
Upside: +718.58%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $201.22
Upside: -36.39%